Market Preview: Our 2015 Forecast
What does my technical research point to for 2015? Let's take a look at some charts that tell the story…
View ArticleMarket Preview: Our 2015 Forecast
What does my technical research point to for 2015? Let's take a look at some charts that tell the story…
View ArticleThe Party Has Just Begun
Of the 13 picks I’ve made in the last 14 months, only one is down by any significant amount. Meanwhile, one of my recommendations has quadrupled, one is close to tripling and three are close to...
View ArticleReal Companies With Real Profits
How’s that “golden age” looking? We examine one of our team’s biggest calls of 2014. Plus: One drug… a universe of 415,000 cancer patients… and $5 billion in potential sales
View ArticleIt’s Time to Sell: Shady Press Releases From Management…
It pains me to tell you that, because this company has so much upside. Remember, it’s sitting on potential oil gushers all over the world... in places like Montana, the United Kingdom and Australia. So...
View ArticleToday’s FDA Trader Notebook
Updates on upcoming Magic Calendar dates, an Ebola stock update, and a full portfolio review…
View ArticleFire Sale In Progress
Three years of profits from the world’s most boring financial crisis. Plus: The chart that says everything about the housing market at year-end 2014
View ArticleAn Emerging Health Threat That Will Kill You — and How to Profit From the...
This invisible killer has become such a concern that the prime minister of the United Kingdom commissioned a study to analyze how bad the threat might become if we stay on our current trajectory. It...
View Article5 Min. Forecast – 2015: The Year the Innovators are Unshackled
2015: The year of unprecedented innovation in biotech… and unprecedented profits, made possible by an event no one sees coming… benefiting patients, doctors and investors alike
View ArticleThe Big End-of-Year Portfolio Review
So far over the past year, we've sold existing positions 26 times, for an average 39% gain. But we still have 22 open positions in the portfolio, which are up an average of 20%. Let's finish off the...
View ArticleA New Year Set to Bring New Payouts and New Strategies!
We’re getting ready to make some big changes – introducing new strategies and recommendations to help you collect bigger payouts than ever before. Here’s a preview of what to expect, plus a look at all...
View ArticleThe Wildest Card of 2015
The neo-Nazis who might soon be armed by Washington. Plus… Crashing oil, crashing ruble, new sanctions: What’s Putin got to lose?
View ArticleMarket Preview: Back to Reality
Here's a look at how our trading system performed in 2014. Plus, a new momentum trade to take on Monday.
View ArticleMarket Preview: Back to Reality
Here's a look at how our trading system performed in 2014. Plus, a new momentum trade to take on Monday.
View ArticleMake 1,529% in 17 Months Because of the First Flu Epidemic in a Decade
Fifteen children have died so far from the flu this season. In North Carolina, seven people died from the flu last week. Indiana just reported that the flu killed 31 people the week of Dec. 27… During...
View ArticleA 1998 Repeat… (Still) Structural Problems… The Oil Price Threat… and More!
Here are the five articles I recommend you read this week. You’ll how a repeat of the 1998 crisis could play out… a Nobel Prize winner’s admission… the threat to your portfolio from oil’s drop… the...
View Article2015: The Year You Become a Stock Market Mercenary
For the rest of the week, I'm going to take a step back and break down the most important moneymaking themes of 2015. These are the potential market-altering trends that could make or break your entire...
View ArticleGold, Silver, Copper, Oil… and British Art
Many good things -- personal and professional -- happened in 2014; and for all good things, I'm grateful. Yet a lot of wheels fell off a lot of buses last year, too. Both in our energy investments and...
View ArticleThe Road Back to $100 Oil
Crude slides below $50… and why it’s headed back to $100 before year-end: The inescapable math that points to an oil shortfall later this year
View ArticleCan GE and BioTime Upend the FDA’s Ancient and Ineffective Drug Testing...
Two weeks ago, I was amused during an analyst presentation in New York when Dr. Stephen Minger, the chief scientist of cellular sciences for General Electric’s Life Sciences division, walked up to a...
View Article